YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis. According to GlobalData, Phase I drugs for Polymyositis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the YTS-109 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YTS-109 overview
YTS-109 is under development for the treatment of systemic lupus erythematosus, primary Sjogren's syndrome, systemic sclerosis, dermatomyositis, polymyositis, immune mediated necrotizing myopathy, anti synthetase syndrome, ANCA-associated vasculitis including microscopic polyvasculitis, granulomatous polyvasculitis and eosinophilic granulomatous polyvasculitis, catastrophic antiphospholipid syndrome. The therapeutic candidate is administered through parenteral route. It consists of T cells engineered to express chimeric T cell receptor synthetic T cell receptor and antigen receptor (STAR).
Bristar Immunotech Biotechnology overview
Bristar Immunotech Biotechnology (Bristar Immunotech) is a biotechnology company focused on development and commercialization of cellular immunotherapy products for various diseases represented by TCR-T. Huaxia Yingtai is headquartered in Beijing, China.
For a complete picture of YTS-109’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
